| Literature DB >> 24913821 |
M Koulmanda1, R S Sampathkumar, M Bhasin, A Qipo, Z Fan, G Singh, B Movahedi, M Duggan, V Chipashvili, T B Strom.
Abstract
The nonimmunologic loss of islets in the pre-, peri-, and early post-islet transplant periods is profound. To determine the potential role that transplantation of only a marginal mass of functioning beta cells may play in triggering late nonimmunologic graft loss, we studied the effect of treatment with alpha-1-antitrypsin (AAT) in the autologous cynomolgus islet transplant model. A marginal mass of autologous islets, that is islets prepared from 70% to 80% of the pancreas, was transplanted at 1600-4100 IEQ/kg into subtotal pancreatectomized, streptozotocin-treated and insulin-deficient diabetic hosts. In this marginal mass islet transplant model, islet function is insidiously lost over time and diabetes recurs in all untreated monkeys by 180 days posttransplantation. Short-term treatment with AAT, an acute phase reactant, in the peri-transplant period serves to terminate inflammation through effects upon expression of TGFβ, NFκB and AKT and favorably altering expression of cell death and survival pathways, as detected by a system biology approach and histology. These effects enabled functional expansion of the islet mass in transplanted hosts such that graft function improves rather than deteriorating over time. © Copyright 2014 The American Society of Transplantation and the American Society of Transplant Surgeons.Entities:
Keywords: Alpha-1-antitrypsin (AAT); inflammation bioinformatics; islet transplantation; monkey
Mesh:
Substances:
Year: 2014 PMID: 24913821 PMCID: PMC4332621 DOI: 10.1111/ajt.12723
Source DB: PubMed Journal: Am J Transplant ISSN: 1600-6135 Impact factor: 8.086